US OptionsDetailed Quotes
CTXR240719C500
- 0.30
- +0.25+500.00%
15min DelayClose Jul 18 15:59 ET
0.35High0.05Low
0.35Open0.05Pre Close12 Volume27 Open Interest0.50Strike Price385.00Turnover0.00%IV-3.15%PremiumJul 19, 2024Expiry Date0.33Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.76Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Citius Pharmaceuticals Stock Discussion
Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
Biotech stocks are racing towards solutions for Cutaneous T-Cell Lymphoma (CTCL), with the market projected to reach $1.38 Billion by 2030.
Citius Pharmaceuticals (NASDAQ: CTXR) is approaching the FDA target date of August 13th for its LYMPHIR product candidate.
The FDA has accepted the resubmission of Citius' Biologics License Application (BLA) for LYMPHIR, an IL-2-based immunother...
Bloodstream Infections - From Threats to Solutions
Investorideas.com published the second part of a series on blood infections treatment, featuring Citius Pharmaceuticals (NASDAQ: CTXR). Citius has made significant advances in its late-stage product candidates, particularly Mino-Lok® for catheter-related bloodstream infections (CRBSIs). The Phase 3 trial of Mino-Lok® showed positive topline results, meeting primary and secondary endpoints with statistical si...
HC Wainwright & Co. Reiterates Buy on Citius Pharma, Maintains $4 Price Target
Benzinga· May 31 13:061min
Citius Pharmaceuticals (CTXR.US)
0.746
+10.29%
HC Wainwright & Co. analyst Vernon Bernardino reiterates Citius Pharma (NASDAQ:CTXR) with a Buy and maintains $4 price target.
Disclaimer: This content is for inform
good morning everyone pay attention CTXR next month 4$
• Considered a new biologic by the FDA, LYMPHIR would potentially be eligible f...
No comment yet